Monosomal karyotype (MK) refers to the presence of two or more distinct autosomal monosomies or a single monosomy associated with a structural abnormality. In acute myeloid leukemia, MK has been shown to be prognostically worse than an otherwise complex karyotype. The current study examines whether the same holds true for myelodysplastic syndromes (MDS). A total of 127 MDS patients (median age 70 years) with a complex karyotype were considered; 106 (83%) met the abovestipulated criteria for MK and 21 (17%) had a complex karyotype without monosomies. Survival was significantly inferior in patients with MK compared with those with a complex karyotype without monosomies (P ¼ 0.01; HR 1.9, 95% confidence interval (95% CI), 1.1-3.3). Multivariable analysis identified MK (P ¼ 0.002), advanced age (P ¼ 0.0004) and bone marrow blast percentage (0.04) as independent risk factors for survival. There was no difference in survival among MK patients further substratified by the presence or absence of monosomy 7 and/or monosomy 5. Although not statistically significant, leukemiafree survival was also worse with MK compared with complex karyotype without monosomies (P ¼ 0.09; HR 2.7, 95% CI 0.8-9.0). MK in MDS identifies a prognostically worse subgroup of patients with a complex karyotype, regardless of whether monosomy 7 or 5 is part of the MK component.
Introduction
Myelodysplastic syndromes (MDS) are a heterogenous group of clonal stem cell disorders characterized by impaired blood cell production (cytopenias) and dysplastic-appearing bone marrows (BMs). Cytogenetic abnormalities at diagnosis have been identified in B20-70% of patients with MDS, with the highest frequencies seen in patients with refractory anemia with excess blasts-1 and -2 (RAEB-1 and RAEB-2).
1,2 MDS with multiple cytogenetic abnormalities, often designated as a complex karyotype (X3 independent clonal abnormalities), is universally considered unfavorable with high rates of leukemic transformation and a poor overall survival (OS). [1] [2] [3] These cytogenetic abnormalities include numerical and structural aberrations, marker chromosomes and ring chromosomes.
A monosomal karyotype (MK) is defined by the presence of two or more distinct autosomal chromosome monosomies or a single autosomal monosomy associated with at least one structural abnormality. 4 In acute myeloid leukemia (AML), MK has been associated with a worse prognosis than an otherwise complex karyotype, regardless of the specific type of autosomal chromosome involved. 4, 5 Whether these observations also hold true for MDS is currently unknown. We performed this study to determine whether MDS with a complex karyotype can be prognostically substratified further on the basis of the presence or absence of MK, and whether prognosis in MDS with MK is in addition affected by the presence or absence of monosomy 7 and/or 5.
Patients and methods

Patient population and diagnostic criteria
The Mayo Clinic database for MDS was used to identify consecutive patients with a complex karyotype, defined by the presence of three or more numerical or structural cytogenetic abnormalities, from 1990 to 2010. All cytogenetic information was re-reviewed and documented according to the 1995 International System for Human Cytogenetic Nomenclature (ISCN) recommendations. 6 An abnormality was considered clonal when at least two metaphases had the same aberration in case of a structural abnormality or an extra chromosome. 6 For classification as a monosomy, the monosomy had to be present in at least three metaphases. 6 An MK was defined by the presence of two or more distinct autosomal chromosome monosomies or a single autosomal monosomy associated with at least one structural abnormality. 4 The patients were then stratified into three subgroups: complex karyotype without monosomies, MK with monosomy 7 and/or 5 and MK with monosomies affecting autosomal chromosomes other than 7 and/or 5. Monosomies of sex chromosomes (ÀX,ÀY), due to the apparent lack of a negative prognostic effect, were not included. 7 The karyotype analysis was based on 20 or more metaphases for X95% of patients included in this study (minimum number of metaphases 15).
The World Health Organization (WHO) criteria were used for MDS diagnosis and leukemic transformation. 8 On the basis of the circulating and BM blast percentages, patients were stratified into three categories: RAEB-1 (2-4% circulating blasts or 5-9% BM blasts), RAEB-2 (5-19% circulating blasts or 10-19% BM blasts) and MDS without excess blasts (o2% circulating blasts or o5% BM blasts). The latter category included patients with refractory anemia with ringed sideroblasts, refractory cytopenias with multilineage dysplasias and MDS-U (MDS unclassifiable). The IPSS (International Prognostic Scoring System) score was calculated for all patients on the basis of the number of cytopenias, cytogenetic profile and percentage of BM blasts. time of initial cytogenetic studies documenting a complex karyotype. Every attempt was made to update follow-up information, by means of the social security death index or a telephone call to the patient, and the ''date of last follow-up'' reflected the current time point and not the last time they were seen at the Mayo Clinic.
Statistical analysis
Numerical variables are summarized as medians and ranges. Categorical variables are described as count and relative frequency (%). Comparison between categorical variables was performed by w 2 -statistics. Comparison between categorical and continuous variables was performed by either the MannWhitney U-test or the Kruskal-Wallis test. The Cox proportional hazards model was used to determine the impact of potential risk factors on survival and Leukemic Transformation (LT). Survival was calculated by Kaplan-Meier plots, taking the interval from the date of diagnosis to death or last contact. A similar analysis was performed for LFS by replacing death with LT as the censoring event. The log-rank test was used to test the homogeneity of OS or LFS curves over different groups. All data were analyzed by using SAS software (SAS, Inc., Cary, NC, USA). All P-values were two-tailed and statistical significance was set at the level of Po0.05.
Results
From 1990 to 2010, a total of 127 consecutive MDS patients (median age 70 years; 79 males) with a complex karyotype were identified (Supplementary Table) . Among them, 106 (83%) met the above-stipulated criteria for MK and 21 (17%) had a complex karyotype without monosomies. Table 1 outlines the clinical and laboratory features of 127 patients with MDS and a complex karyotype, stratified by the presence or absence of an MK. All patients with the exception of three had an IPSS score of intermediate-2 (75%) or higher (23%), with 91% being transfusion dependent at diagnosis. In all, 38 (36%) patients with an MK and nine (43%) with a complex karyotype had therapy-related MDS (t-MDS) with previous exposure to chemotherapy/radiotherapy for non-Hodgkin's lymphoma-16 (34%), plasma cell dyscracias-11 (23%, all with previous exposure to melphalan), Hodgkin's disease-5 (11%), breast cancer-5 (11%), autoimmune diseases-4 (9%, all with previous exposure to azathioprine), AML-3 (6%) and chronic lymphocytic leukemia-2 (4%).
The MK in the 106 patients included monosomy 7 and/or 5 in 73 (69%) cases. In all, 46 cases (63%) had an MK with monosomy 7, 12 (16%) had an MK with monosomy 5 and 15 (21%) had an MK with both monosomy 7 and 5. A monosomy of every single autosomal chromosome (1-22) was encountered in this group. The most common monosomies were 7 and 5, and the least common was monosomy 1 (n ¼ 1). Table 2 outlines the clinical and laboratory features of 106 patients with MDS with a complex MK, stratified by the presence or absence of monosomy 7 and/or 5. The three complex karyotype subsets (that is, complex without monosomies vs MK that included monosomy 7 and/or 5 vs MK excluding monosomy 7 and/or 5) were not significantly different in terms of age and sex distribution, hemoglobin level, leukocyte or platelet count, circulating or BM, blast percentages, MDS subtypes or IPSS risk score.
The OS was significantly inferior in patients with MK compared with those with a complex karyotype without monosomies (P ¼ 0.01; HR 1.9, 95% confidence interval (95% CI), 1.1-3.3). The median survival of patients with a complex karyotype without monosomies and MK was 13 months (2-year survival 23%) and 7 months (2-year survival 6%), respectively ( Figure 1 ). The median survival of patients with an MK with monosomy 7 and/or 5 and an MK excluding monosomy 7 and/or 5 was similar at 7 months (2-year survival 4 and 12%, respectively) ( Figure 2 ). Multivariable analysis identified MK (P ¼ 0.002), advanced age (P ¼ 0.0004), increased BM blast percentage (0.04), but not IPSS risk category (P ¼ 0.34), as independent risk factors for survival. Table 3 outlines the prognostic variables affecting survival of 127 patients with MDS with a complex karyotype, stratified on the basis of the presence or absence of an MK. The rate of leukemic transformation was 14% (n ¼ 3), 23% (n ¼ 17) and 21% (n ¼ 7) for patients with a complex karyotype, MK with monosomy 7 and/or 5 and MK excluding monosomy 7 and/or 5, respectively (Figures 3 and 4) . Although not statistically significant, LFS was worse in patients with MK compared with those with a complex karyotype (P ¼ 0.09; HR 2.7, 95% CI, 0.8-9.0) (Figure 3) . None of the aforementioned variables significantly affected LFS. Table 4 outlines the prognostic variables affecting leukemic transformation for 127 patients with MDS with a complex karyotype stratified by the presence or absence of an MK.
Discussion
Cytogenetic information forms the backbone for diagnostic, prognostic and therapeutic strategies in both acute and chronic myeloid malignancies. The IPSS classifies cytogenetic findings in MDS into three risk groups: good (normal, ÀY, del(5q)), poor (complex and/or any chromosome 7 abnormality) and intermediate (all other abnormalities).
3 However, such broad categorization ignores prognostic diversity among patients with a complex karyotype and also in those with an intermediate-risk cytogenetic profile. 3, 9 In general, a complex karyotype in MDS or AML is associated with a median survival of o1 year 1, 2 However, two recent studies in AML have suggested that MK represents a prognostically more dire subcategory of complex karyotype. 4, 5 In the first study by Breems et al., MK, irrespective of the particular chromosome involved, predicted an inferior outcome (4-year OS, 4 ± 1%), compared with what was seen with complex karyotype without monosomies (4-year OS, 26 ± 2%). 4 In the second study, Medeiros et al. demonstrated The results of this study indicate that the presence of MK is as detrimental in MDS as it is in AML. OS and LFS in MDS with a complex karyotype were significantly inferior in the presence of MK as opposed to in its absence (OS; P ¼ 0.01; HR 1.9, 95% CI, 1.1-3.3, LFS; P ¼ 0.09; HR 2.7, 95% CI, 0.8-9.0). Furthermore, the adverse prognostic effect of MK was evident both in the presence and absence of monosomy 7/5, which suggests that tumor suppressor or other critical genes are not necessarily clustered in specific chromosomes but are instead distributed across several chromosomes. In other words, although chromosome 5 or 7 abnormalities are prevalent in MDS, their wellknown association with poor prognosis might be tied to the fact that these abnormalities often involve gross chromosomal loss. From a management standpoint, although the 2-year survival difference in patients with MK (6%) is significantly inferior to those with a complex karyotype without MK (23%), both groups of patients require equally aggressive treatment approaches, when feasible. In this regard, it is comforting to note that the outcome of allogeneic stem cell transplant in AML with a complex karyotype (40% OS for patients receiving transplant in complete remission 1) was not influenced further by the presence or absence of MK. 10 Future studies should address the prognostic relevance of distinguishing MK from sole autosomal monosomies and whole-chromosome losses from gross interstitial deletions.
